Literature DB >> 9613716

Mechanisms of MPTP toxicity.

S Przedborski1, V Jackson-Lewis.   

Abstract

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces an experimental model of Parkinson's disease (PD). It replicates most of the clinical features of PD as well as the main biochemical and pathologic hallmarks of the disease. Although the MPTP model departs from PD in several aspects, it is thought that important insights into the neurodegenerative process of PD may be obtained by elucidating the molecular mechanism of MPTP. In this article, we summarize the different steps of the complex metabolic pathway of MPTP and show how they may be implicated in predisposing individuals to PD. We also outline findings pertinent to the mode of action of MPTP including overproduction of free radicals, implication of nitric oxide, nitration of tyrosine, impairment of mitochondrial respiration, and occurrence of apoptosis. All of these factors may participate in the cascade of deleterious events that ultimately lead to the death of dopaminergic neurons after MPTP administration. Because of the similarity between PD and the MPTP model, we are speculating that a similar scenario may underlie the neurodegenerative process in PD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613716

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  85 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.

Authors:  V Viswanath; Y Wu; R Boonplueang; S Chen; F F Stevenson; F Yantiri; L Yang; M F Beal; J K Andersen
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 3.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

4.  Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production.

Authors:  Zhi-Guo Zhang; Lin Wu; Ju-Lei Wang; Jian-Dong Yang; Jing Zhang; Jian Zhang; Li-Hong Li; Yi Xia; Li-Bo Yao; Huai-Zhou Qin; Guo-Dong Gao
Journal:  Mol Cell Biochem       Date:  2012-01-26       Impact factor: 3.396

5.  The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.

Authors:  Corrado Corti; Giuseppe Battaglia; Gemma Molinaro; Barbara Riozzi; Anna Pittaluga; Mauro Corsi; Manolo Mugnaini; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

6.  Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease.

Authors:  Li-Ping Liang; Jie Huang; Ruth Fulton; Jennifer N Pearson-Smith; Brian J Day; Manisha Patel
Journal:  Toxicol Appl Pharmacol       Date:  2017-04-08       Impact factor: 4.219

7.  N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice.

Authors:  Rosalia Crupi; Daniela Impellizzeri; Marika Cordaro; Rosalba Siracusa; Giovanna Casili; Maurizio Evangelista; Salvatore Cuzzocrea
Journal:  Mol Neurobiol       Date:  2018-03-19       Impact factor: 5.590

Review 8.  Parkinson's disease and enhanced inflammatory response.

Authors:  Iva Stojkovska; Brandon M Wagner; Brad E Morrison
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

Review 9.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

10.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.